[go: up one dir, main page]

WO2012061469A3 - Crystalline forms of pralatrexate - Google Patents

Crystalline forms of pralatrexate Download PDF

Info

Publication number
WO2012061469A3
WO2012061469A3 PCT/US2011/058913 US2011058913W WO2012061469A3 WO 2012061469 A3 WO2012061469 A3 WO 2012061469A3 US 2011058913 W US2011058913 W US 2011058913W WO 2012061469 A3 WO2012061469 A3 WO 2012061469A3
Authority
WO
WIPO (PCT)
Prior art keywords
pralatrexate
crystalline forms
compositions
crystalline
relapsed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/058913
Other languages
French (fr)
Other versions
WO2012061469A2 (en
Inventor
Paolo Simone Tiseni
Tomislav Biljan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sicor Inc
Original Assignee
Sicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sicor Inc filed Critical Sicor Inc
Publication of WO2012061469A2 publication Critical patent/WO2012061469A2/en
Publication of WO2012061469A3 publication Critical patent/WO2012061469A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This patent application provides crystalline forms of Pralatrexate, in particular, Form A, Form B and Form C, pharmaceutical compositions comprising a crystalline form of Pralatrexate and at least one pharmaceutically acceptable excipient, and methods of using one of the compositions for the treatment of relapsed or refractory peripheral T-cell lymphoma.
PCT/US2011/058913 2010-11-02 2011-11-02 Crystalline forms of pralatrexate Ceased WO2012061469A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40926310P 2010-11-02 2010-11-02
US61/409,263 2010-11-02

Publications (2)

Publication Number Publication Date
WO2012061469A2 WO2012061469A2 (en) 2012-05-10
WO2012061469A3 true WO2012061469A3 (en) 2013-05-02

Family

ID=46025080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/058913 Ceased WO2012061469A2 (en) 2010-11-02 2011-11-02 Crystalline forms of pralatrexate

Country Status (1)

Country Link
WO (1) WO2012061469A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177713A1 (en) * 2012-05-31 2013-12-05 Alphora Research Inc. Process for preparation of an antifolate agent
WO2014020553A1 (en) 2012-08-03 2014-02-06 Fresenius Kabi Oncology Ltd. Salts of pralatrexate
US9783542B2 (en) 2012-11-02 2017-10-10 Hetero Research Foundation Process for pralatrexate
CN104418859B (en) * 2013-09-09 2016-06-22 上海医药工业研究院 The crystal formation of Pralatrexate, containing its pharmaceutical composition and its preparation method and application
CN104628727B (en) * 2013-11-07 2018-08-21 正大天晴药业集团股份有限公司 A kind of crystal form of Pralatrexate and preparation method thereof
CN105272983B (en) * 2014-06-12 2021-01-15 连云港润众制药有限公司 High-purity pradaqusha solid and preparation method thereof
AU2017308159B2 (en) 2016-08-12 2023-08-10 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
US20180236098A1 (en) 2016-08-12 2018-08-23 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
CN108069971B (en) * 2016-11-18 2021-02-12 鲁南制药集团股份有限公司 Refining method of pralatrexate intermediate
US12239734B2 (en) 2018-02-07 2025-03-04 L.E.A.F. Holdings Group Llc Gamma polyglutamated raltitrexed and uses thereof
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
WO2019157146A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
EP3749312A4 (en) 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC LOMETREXOL ALPHA-POLYGLUTAMATE AND ASSOCIATED USES
CA3090387A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
WO2019157123A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
JP7491572B2 (en) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー Alpha polyglutamated pemetrexed and uses thereof
JP7514533B2 (en) 2018-02-07 2024-07-11 エル．イー．エー．エフ． ホールディングス グループ エルエルシー Alpha polyglutamylated tetrahydrofolate and uses thereof
CA3090483A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
CA3090389A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
US12048766B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
CA3090943A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
US12290518B2 (en) 2018-02-14 2025-05-06 L.E.A.F. Holdings Group Llc Gamma polyglutamated methotrexate and uses thereof
EP3752156A4 (en) * 2018-02-14 2021-10-27 L.E.A.F Holdings Group LLC PRALATREXATE GAMMA-POLYGLUTAMATE AND ASSOCIATED USES
WO2025059556A1 (en) * 2023-09-15 2025-03-20 Acrotech Biopharma Inc. Compositions comprising pralatrexate for subcutaneous administration and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028071A (en) * 1996-07-17 2000-02-22 Sloan-Kettering Institute For Cancer Research Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354751A (en) 1992-03-03 1994-10-11 Sri International Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028071A (en) * 1996-07-17 2000-02-22 Sloan-Kettering Institute For Cancer Research Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DEGRAW J I ET AL: "SYNTHESIS AND ANTITUMOR ACTIVITY OF 10-PROPARGYL-10-DEAZAAMINOPTERIN", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 36, 1 January 1993 (1993-01-01), pages 2228 - 2231, XP000941891, ISSN: 0022-2623, DOI: 10.1021/JM00067A020 *

Also Published As

Publication number Publication date
WO2012061469A2 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
WO2012061469A3 (en) Crystalline forms of pralatrexate
WO2010132882A3 (en) Sublingual dexmedetomidine compositions and methods of use thereof
WO2007027527A3 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2007150077A8 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2012048099A3 (en) Nanoparticle-loaded cells
WO2012055567A3 (en) Use of malononitrilamides in neuropathic pain
WO2011057262A3 (en) Treatment of infections with tp receptor antagonists
EP2214770A4 (en) Methods, kits, and compositions for administering pharmaceutical compounds
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
WO2013057570A3 (en) Acrylic polymer formulations
AU2008339918A1 (en) Medicament for the treatment of cancer of the pancreas
WO2010083385A3 (en) Compounds for reducing drug resistance and uses thereof
GB0718446D0 (en) Compositions and methods for the treatment of infection
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
WO2011009890A3 (en) Use of azabicycloalkyl derivatives or pyrrolidine - 2 - one derivatives for the treatment or prevention of ataxia
WO2010091384A3 (en) Cadherin-11 inhibitors and methods of use thereof
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
AP2012006292A0 (en) Topical use of hydroxytyrosol and derivatives for the prevention of HIV infection.
IL212942A (en) Rifamycin derivatives, process for their preparation, pharmaceutical compositions comprising the same and uses thereof
WO2013074871A3 (en) Humanin analogs
WO2010148314A3 (en) Preparation of esomeprazole and its pharmaceutically acceptable salts

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11838727

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11838727

Country of ref document: EP

Kind code of ref document: A2